Bundibugyo Ebola: Negative Surveillance Results Do Not Resolve the Vaccine Development Gap

On October 11, Kenya's Ministry of Health reported no additional Ebola infections following testing of 293 samples associated with 289 alerts. Of 122 identified contacts linked to the country's first imported case, 108 were in quarantine and had not developed symptoms.

The imported case was confirmed as Bundibugyo virus disease, associated with the ongoing outbreak in the Democratic Republic of Congo, which has exceeded 8,000 reported cases.

Importantly, the World Health Organization confirms that no licensed vaccine or therapeutic specifically approved for Bundibugyo virus disease currently exists. Reuters

Sources: Reuters, October 11 · WHO vaccine guidance

Why it matters strategically

The immediate surveillance results are reassuring, but they do not establish that all transmission risks have been eliminated.

The more important pharmaceutical question concerns the economics and feasibility of developing vaccines against outbreak-driven pathogens.

In June, Gavi, the Vaccine Alliance committed up to $40 million to accelerate access to Bundibugyo vaccines, including potential manufacturing support.

Candidate developers include IAVI, Oxford University and Serum Institute of India, Moderna, and Public Health Vaccines.

WHO has also identified candidate therapeutics for clinical evaluation, including MBP134, maftivimab, and remdesivir.